Gene therapy patients monitored for years to ensure lasting safety

NCT ID NCT05145062

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study follows 8 people who received a one-time gene therapy (BIVV003 for sickle cell disease or ST-400 for beta-thalassemia) to see if it remains safe and effective over many years. Researchers will track serious side effects, survival, and blood markers like hemoglobin levels. Participants must have already received the therapy in an earlier study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSFUSION-DEPENDENT BETA-THALASSEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

beta thalassemia beta-thalassemia major hematologic disorder lymphatic system disorder sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

  • Children's Healthcare of Atlanta

    Atlanta, Georgia, 30329, United States

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • UCSF Benioff Children's Hospital

    Oakland, California, 94609, United States

  • University of California Davis Health System

    Sacramento, California, 95817, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States